Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

Functional Homomers and Heteromers of Dopamine D2Land D3Receptors Co-exist at the Cell Surface

(2012) Chantevy Pou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

(2012) Mark J. Millan et al.   NATURE REVIEWS DRUG DISCOVERY

Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

(2012) Georges Vauquelin et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach

(2012) Manolo Mugnaini et al.   NEUROPSYCHOPHARMACOLOGY

The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions

(2012) Brandon Abbs et al.   SCHIZOPHRENIA RESEARCH

Are you or aren’t you? Challenges associated with physiologically identifying dopamine neurons

(2012) Mark A. Ungless et al.   TRENDS IN NEUROSCIENCES

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

(2011) David J. G. Watson et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

(2011) Laura Redden et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A 4 Hz Oscillation Adaptively Synchronizes Prefrontal, VTA, and Hippocampal Activities

(2011) Shigeyoshi Fujisawa et al.   NEURON

Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

(2011) David JG Watson et al.   NEUROPSYCHOPHARMACOLOGY

Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

(2011) Romina Mizrahi et al.   SCHIZOPHRENIA RESEARCH

Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo

(2011) Jean-Dominique Gallezot et al.   SYNAPSE

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

(2010) Graham Searle et al.   BIOLOGICAL PSYCHIATRY

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures

(2010) Mark J. Millan et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Behavioral Indices in Antipsychotic Drug Discovery

(2010) R. D. Porsolt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy

(2010) Andri C. Tziortzi et al.   NEUROIMAGE

In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO

(2010) Ragy R Girgis et al.   NEUROPSYCHOPHARMACOLOGY

Dopamine D1 but not D3 receptor is critical for spatial learning and related signaling in the hippocampus

(2010) B. Xing et al.   NEUROSCIENCE

Enhanced cognitive performance of dopamine D3 receptor “knock-out” mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems

(2010) Vincenzo Micale et al.   PHARMACOLOGICAL RESEARCH

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors

(2009) Ariel Graff-Guerrero et al.   ARCHIVES OF GENERAL PSYCHIATRY

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

(2009) Roberto Maggio et al.   CURRENT OPINION IN PHARMACOLOGY

Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor

(2009) Alex V. Yarkov et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925

(2009) Ariel Graff-Guerrero et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3Receptor Antagonists

(2009) Fabrizio Micheli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

(2009) S. M. Grauer et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A role for dopamine D2 receptors in reversal learning

(2009) D.A. DeSteno et al.   NEUROSCIENCE

Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes

(2009) Heike Tost et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence

(2008) Christian Heidbreder   CNS & Neurological Disorders-Drug Targets

Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists

(2008) Florence Loiseau et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15

(2008) István Gyertyán et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138

(2008) Mark J. Millan et al.   THERAPIE

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans

(2007) Ariel Graff-Guerrero et al.   HUMAN BRAIN MAPPING